Artios raises $84M for developing cancer drugs targeting DNA repair pathway
The UK firm is developing drugs targeting DNA damage response, similar to approved PARP inhibitors for gynecologic cancers.
SV Health Investors rebranding reflects increased investment in health IT
The investment firm formerly known as SV Life Sciences has shifted its investment allocation for healthcare services/digital health companies from 25 percent to 40 percent.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.